Genetic testing startup Adela raised USD 48 million in funding, bringing total funds raised to USD 108 million. Labcorp joined the round as a new investor, with existing investors OrbiMed, Decheng Capital, F-Prime Capital, Deerfield Management, and RA Capital Management also participating.
The funding will be used to enhance Adela's technological capabilities, commercialize its tissue-agnostic measurable residual disease (MRD) product, and continue developing its multi-cancer early detection product.
Adela is focused on developing blood tests for MRD monitoring and early cancer detection. Its genome-wide methylation analysis technology is able to capture genomic information used for the early detection, diagnosis, and management of cancer. The platform captures biologic-relevant genomic data to inform treatment decisions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.